Even with our pragmatic design (newly diagnosed breast cancer, postmenopausal, >2 cm clinical or radiological confirmed, subsequently identified hormone receptor positive disease) 197 patients had to be approached or screened in order to identify the 32 potentially eligible patients who consented to the study. This evidence concerns the gene NR4A1 and breast carcinoma.